PURPOSE: To investigate the outcomes of simultaneous correction of presbyopia and ametropia by a bi-aspheric cornea modulation technique, based on the creation of a central area hyperpositive for near vision and leaving the pericentral cornea for far vision in hyperopic, emmetropic, and myopic presbyopic patients. SETTING: Sixty eyes of 30 patients were treated with the PresbyMAX technique by one surgeon (D.U.) at the Eye Hospital Bellevue, Kiel, Germany. METHODS: Twenty eyes with hyperopic presbyopia, 20 eyes with emmetropic presbyopia, and 20 eyes with myopic presbyopia underwent Femto-Lasik, and were assessed up to 6 months postoperatively. All eyes underwent cornea treatment using the PresbyMAX® software, delivering a bi-aspheric multifocal ablation profile developed by SCHWIND eye-tech-solutions (Kleinostheim, Germany). All flaps were created by Ziemer LDV Femtolaser (Port, Switzerland). RESULTS: The mean binocular distance of uncorrected visual acuity (DUCVA) improved in the hyperopic group from 0.28 ± 0.29 logMAR to -0.04 ± 0.07 logMAR, in the emmetropic group from -0.05 ± 0.07 logMAR to 0.02 ± 0.11 logMAR, and in the myopic group from 0.78 ± 0.27 logMAR to 0.09 ± 0.08 logMAR. The mean binocular near uncorrected visual acuity (NUCVA) increased in the hyperopic group from 0.86 ± 0.62 logRAD to 0.24 ± 0.23 logRAD, and in the emmetropic group from 0.48 ± 0.14 logRAD to 0.18 ± 0.11 logRAD. The myopic presbyopes showed a decrease of the mean binocular NUCVA from 0.04 ± 0.19 logRAD to 0.12 ± 0.18 logRAD. The mean postoperative spherical equivalent for distance refraction was -0.13 ± 0.61 D for the hyperopic presbyopia, -0.43 ± 0.35 D for the emmetropic presbyopia, and -0.68 ± 0.42 D for the myopic presbyopia group, whereas the software took aim at -0.50 D in all groups. CONCLUSIONS: In presbyopic patients without symptomatic cataracts, but refractive errors, PresbyMAX® will decrease the presbyopic symptoms and correct far distance refraction in the same treatment, offering spectacle-free vision in daily life in most of the treated patients. Further investigation is necessary to evaluate the overall benefit of this procedure.
PURPOSE: To investigate the outcomes of simultaneous correction of presbyopia and ametropia by a bi-aspheric cornea modulation technique, based on the creation of a central area hyperpositive for near vision and leaving the pericentral cornea for far vision in hyperopic, emmetropic, and myopic presbyopic patients. SETTING: Sixty eyes of 30 patients were treated with the PresbyMAX technique by one surgeon (D.U.) at the Eye Hospital Bellevue, Kiel, Germany. METHODS: Twenty eyes with hyperopic presbyopia, 20 eyes with emmetropic presbyopia, and 20 eyes with myopic presbyopia underwent Femto-Lasik, and were assessed up to 6 months postoperatively. All eyes underwent cornea treatment using the PresbyMAX® software, delivering a bi-aspheric multifocal ablation profile developed by SCHWIND eye-tech-solutions (Kleinostheim, Germany). All flaps were created by Ziemer LDV Femtolaser (Port, Switzerland). RESULTS: The mean binocular distance of uncorrected visual acuity (DUCVA) improved in the hyperopic group from 0.28 ± 0.29 logMAR to -0.04 ± 0.07 logMAR, in the emmetropic group from -0.05 ± 0.07 logMAR to 0.02 ± 0.11 logMAR, and in the myopic group from 0.78 ± 0.27 logMAR to 0.09 ± 0.08 logMAR. The mean binocular near uncorrected visual acuity (NUCVA) increased in the hyperopic group from 0.86 ± 0.62 logRAD to 0.24 ± 0.23 logRAD, and in the emmetropic group from 0.48 ± 0.14 logRAD to 0.18 ± 0.11 logRAD. The myopic presbyopes showed a decrease of the mean binocular NUCVA from 0.04 ± 0.19 logRAD to 0.12 ± 0.18 logRAD. The mean postoperative spherical equivalent for distance refraction was -0.13 ± 0.61 D for the hyperopic presbyopia, -0.43 ± 0.35 D for the emmetropic presbyopia, and -0.68 ± 0.42 D for the myopic presbyopia group, whereas the software took aim at -0.50 D in all groups. CONCLUSIONS: In presbyopic patients without symptomatic cataracts, but refractive errors, PresbyMAX® will decrease the presbyopic symptoms and correct far distance refraction in the same treatment, offering spectacle-free vision in daily life in most of the treated patients. Further investigation is necessary to evaluate the overall benefit of this procedure.
Authors: Norberto López-Gil; Vicente Fernández-Sánchez; Richard Legras; Robert Montés-Micó; Francisco Lara; Jean Luc Nguyen-Khoa Journal: Invest Ophthalmol Vis Sci Date: 2008-04 Impact factor: 4.799
Authors: Robert Montés-Micó; Enrique España; Inmaculada Bueno; W Neil Charman; José L Menezo Journal: Ophthalmology Date: 2004-01 Impact factor: 12.079
Authors: Robert Edward T Ang; Emerson M Cruz; Alex U Pisig; Maria Luisa Patricia C Solis; Rosalie Mae M Reyes; Gerhard Youssefi Journal: Eye Vis (Lond) Date: 2016-12-08